XSHE
000952
Market cap335mUSD
Oct 09, Last price
6.69CNY
1D
2.45%
1Q
18.62%
Jan 2017
-58.00%
Name
Hubei Guangji Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hubei Guangji Pharmaceutical Co., Ltd. engages in the production and operation of pharmaceutical raw materials, pharmaceutical preparations, and feed additives. It specializes in production of vitamin B2, B6 and pharmaceutical products. Vitamin B2, is also known as riboflavin. it is used in medicine APIs (Active Pharmaceutical Ingredient), feed additives, and food additives. Its products are divided into raw material series products and preparation series products. The series of raw materials are pharmaceutical grade, food grade, 98% feed grade, 80% feed grade nuclear yellow and riboflavin sodium phosphate. The preparation series products are oral solid preparations and large infusions. The company was founded on May 28, 1993 and is headquartered in Wuxue, China.
Key people
Ligang Hu
Chairman of the Board · since 2024
Yi Xiong
Chief Financial Officer · since 2024
Cheng Gong
General Manager, Director · since 2024
Lin Yang
General Manager · since 2024
Zhanghua Cheng
Deputy General Manager · since 2011
Zhi Fang
Deputy General Manager, Director, Chief Engineer · since 2024
Mingfeng Hu
Deputy General Manager · since 2024
Zhengdong Lu
Deputy General Manager · since 2018
Zhongyi Ruan
Deputy General Manager · since 2018
Xin Wang
Deputy General Manager · since 2011
Yanhua Zhao
Deputy General Manager · since 2024
Xinghu Yang
Secretary of the Board · since 2025
Bin Zheng
Secretary of the Board · since 2021
Shaozhi Guo
Deputy General Manager, Director · since 2018
Bo Liu
Director · since 2024
Shoudong Shi
Director · since 2024
Wei Guo
Independent Director · since 2024
Kui Hong
Independent Director · since 2024
Jianming Mei
Independent Director · since 2024
Headquarters & legal address
湖北武穴市江堤路1号
黄冈市, HB 430000
CN
黄冈市, HB 430000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||